Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway

Fig. 6

ATM inhibitor suppresses tumor metastasis in cisplatin-resistant NSCLC cells. a Cell death effect of CP compound in vitro. To show the effect of CP compound on animal model is not caused by cell death in vivo, we treated cells in vitro the CP466722 for long term treatment more than 72 h by MTT assay. b-d ATM inhibitor suppresses lung metastasis in cisplatin-resistant NSCLC cells. A549P and A549CisR cells were injected into lung through pleural. Tumor growth and metastasis were weekly monitored for 8 weeks by IVIS Images machine. Representative mice were taken 8 weeks after the injections and shown in (b). Numbers of tumor metastasis in each group was shown in (c). Representative imaging of tumor metastasis were presented in (d). e HE staining of metastatic tumors. A549P and A549CisR xenografts tumor tissues obtained from CP466722-treated mice or control mice were stained by HE, confirming the harvested the metastatic tumors. f ATM inhibitor (CP466722) suppresses EMT in vivo. A549P and A549CisR xenografts tumor tissues obtained from CP466722-treated mice or control mice were subjected to IHC staining using the antibodies anti-EMT-related genes. Represented images were shown in left panel. Quantitation of positively stained cells was shown on right panel. g Ki67 expression in vivo. A549P and A549CisR xenografts tumor tissues obtained from CP466722-treated mice or control mice were subjected to IHC staining using Ki67. *p < 0.05, **p < 0.01, ***p < 0.001, compared to the control treatment

Back to article page